Star investor Cathie Wood is usually one to follow. In less than a year, the biotech company ended development of two candidates in one of its rare-disease programs. Now the question is, should you follow Wood's lead and consider shares of this biotech company?
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting